구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | nivolumab (Opdivo, Ipilimumab and nivolumab) Bristol Myers Squibb·Uveal Melanoma, Metastatic 59 trials |
|---|---|
Overview Program | Ipilimumab and nivolumab |
Overview Company | Bristol Myers Squibb |
Overview Modality | ANTIBODY |
Overview Target | Uveal Melanoma, Metastatic |
Overview Indication | Mesothelioma; Pancreatic Cancer |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
Overview Content status | Limited Data |
Overview Data Confidence | Data Confidence · Low |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
MoA Mechanism | checkpoint blockade-mediated eradication of bone metastasis: case report |
MoA Biomarker | PD-L1) expression |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | PD |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | Upadacitinib salvage for refractory immune checkpoint inhibitor colitis complicated by cytomegalovirus infection.. Immune checkpoint inhibitor colitis is a common immune-related adverse event associated with immunotherapy and may be refractory to corticosteroids and biologic therapy. Evidence guiding management beyond anti-tumour necrosis factor and anti-integrin therapy remains limited. We report… |
Clinical Safety signal | Upadacitinib salvage for refractory immune checkpoint inhibitor colitis complicated by cytomegalovirus infection.. Immune checkpoint inhibitor colitis is a common immune-related adverse event associated with immunotherapy and may be refractory to corticosteroids and biologic therapy. Evidence guiding management beyond anti-tumour necrosis factor and anti-integrin therapy remains limited. We report… |
Clinical Selected reported efficacy | ORR 77.8% |
Clinical Reported ORR | 77.8% |
Clinical Reported PFS | NA |
Clinical Result source | ClinicalTrials.gov NCT03195478 |
Clinical Program phase | PHASE_2 |
Clinical Trial ref | NCT03195478 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | nivolumab (Opdivo, Ipilimumab and nivolumab) Bristol Myers Squibb·Uveal Melanoma, Metastatic 59 trials |
|---|---|
Overview Program | Ipilimumab and nivolumab |
Overview Company | Bristol Myers Squibb |
Overview Modality | ANTIBODY |
Overview Target | Uveal Melanoma, Metastatic |
Overview Indication | Mesothelioma; Pancreatic Cancer |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
Overview Content status | Limited Data |
Overview Data Confidence | Data Confidence · Low |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
MoA Mechanism | checkpoint blockade-mediated eradication of bone metastasis: case report |
MoA Biomarker | PD-L1) expression |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | PD |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | Upadacitinib salvage for refractory immune checkpoint inhibitor colitis complicated by cytomegalovirus infection.. Immune checkpoint inhibitor colitis is a common immune-related adverse event associated with immunotherapy and may be refractory to corticosteroids and biologic therapy. Evidence guiding management beyond anti-tumour necrosis factor and anti-integrin therapy remains limited. We report… |
Clinical Safety signal | Upadacitinib salvage for refractory immune checkpoint inhibitor colitis complicated by cytomegalovirus infection.. Immune checkpoint inhibitor colitis is a common immune-related adverse event associated with immunotherapy and may be refractory to corticosteroids and biologic therapy. Evidence guiding management beyond anti-tumour necrosis factor and anti-integrin therapy remains limited. We report… |
Clinical Selected reported efficacy | ORR 77.8% |
Clinical Reported ORR | 77.8% |
Clinical Reported PFS | NA |
Clinical Result source | ClinicalTrials.gov NCT03195478 |
Clinical Program phase | PHASE_2 |
Clinical Trial ref | NCT03195478 |
추천 비교
추천 비교